RESUMEN
Stroke is a major cause of fatalities and disabilities around the world, yet the available treatments for it are still limited. The quest for more efficacious drugs and therapies is still an arduous task. LY2922470 is currently used as a G protein-coupled receptor 40 (GPR40) agonist for the treatment of type 2 diabetes. Previous studies have reported protective effects of other GPR40 activators on the brain; however, it remains unclear whether LY2922470 could be a new stroke therapy and improve the stroke-induced brain damage. Here, we first reveal that the transcriptomic gene signature induced by LY2922470 is highly similar to those induced by some agents being involved in defending from cerebrovascular accidents and transient ischemic attacks, including acetylsalicylic acid, progesterone, estradiol, dipyridamole, and dihydroergotamine. This result thus suggests that LY2922470 could have protective effects against ischemic stroke. As a result, further experiments show that giving the small molecule LY2922470 via oral administration or intraperitoneal injection was seen to have a positive effect on neuroprotection with a reduction in infarct size and an improvement in motor skills in mice. Finally, it was demonstrated that LY2922470 could successfully mitigate the harm to the brain caused by ischemic stroke.
Asunto(s)
Lesiones Encefálicas , Isquemia Encefálica , Diabetes Mellitus Tipo 2 , Accidente Cerebrovascular Isquémico , Accidente Cerebrovascular , Ratones , Animales , Accidente Cerebrovascular/tratamiento farmacológico , Accidente Cerebrovascular/prevención & control , Isquemia Encefálica/tratamiento farmacológico , Receptores Acoplados a Proteínas G/genética , Receptores Acoplados a Proteínas G/agonistas , Ratones Endogámicos C57BLRESUMEN
Rationale: Pulmonary hypertension (PH) secondary to lung fibrosis belongs to WHO Group III, one of the most common subgroups of PH; however, it lacks effective treatment options. Cholinesterase inhibitor donepezil (DON) has been shown to effectively improve Group I PH. However, its effects on Group III PH are unknown. Methods: A lung fibrosis-induced PH mouse model was constructed using a single intratracheal instillation of bleomycin (BLM), after which DON was administered daily. Pulmonary artery and right ventricle (RV) remodeling were evaluated at the end of the study. Lung tissue in each group was analyzed using RNA sequencing, and the results were further verified with datasets from patients with PH. The mechanisms underlying DON-induced effects on PH were verified both in vivo and in vitro. Results: DON effectively improved pulmonary artery and RV remodeling in the BLM-induced mouse model. Transcriptomic profiles of lung tissue indicated that the expression of inflammatory and fibrotic genes was significantly changed in this process. In the animal model and patients with PH, T helper 17 lymphocytes (Th17) were the most common inflammatory cells infiltrating the lung tissue. DON significantly inhibited lung fibroblast activation; thus, preventing lung fibrosis and reducing the inflammatory response and Th17 cell infiltration in the BLM-induced lung tissue. In addition, Th17 cells could activate lung fibroblasts by secreting IL17A, and DON-mediated inhibition of Th17 cell differentiation was found to depend on the α7nAchR-JAK2-STAT3 pathway. Conclusion: DON can alleviate lung fibrosis and PH in an experimental mouse model. It inhibited pro-inflammatory Th17 cell differentiation, which is dependent on a cholinergic receptor pathway, thereby regulating fibroblast activation.
Asunto(s)
Hipertensión Pulmonar , Fibrosis Pulmonar , Ratones , Animales , Fibrosis Pulmonar/inducido químicamente , Hipertensión Pulmonar/metabolismo , Hipertensión Pulmonar/patología , Células Th17/metabolismo , Donepezilo/efectos adversos , Donepezilo/metabolismo , Pulmón/patología , Fibrosis , Bleomicina/toxicidadRESUMEN
Bleeding is a major adverse event during clopidogrel treatment in patients with acute coronary syndrome (ACS). However, the potential mechanism affecting bleeding among individuals is unclear. Herein, we investigated the involvement of CYP2C19*2 and CYP2C19*3, as well as 10 miRNA polymorphisms, in bleeding in Chinese patients with ACS during the first year of clopidogrel treatment. The miR-6076 rs1463411 G polymorphism was significantly associated with the risk of bleeding (P < 0.001), and the rs1463411 GT + GG genotype significantly increased the risk of bleeding (adjusted odds ratio, 6.09; 95% confidence interval, 1.09-34.0; P < 0.001). Dual luciferase assay showed that miR-6076 significantly decreased the mRNA expression of P2RY12 (P < 0.05). P2RY12 mRNA and protein levels were significantly lower in cells transfected with miR-6076-G than in cells transfected with miR-6076-T (P < 0.05). The findings indicate that miR-6076 targets P2RY12 mRNA and that miR-6076 rs1463411 T/G polymorphisms differentially regulate P2RY12 mRNA and protein levels in cells. rs1463411 G polymorphism may increase the risk of bleeding during clopidogrel treatment in patients with ACS.
Asunto(s)
Síndrome Coronario Agudo , MicroARNs , Intervención Coronaria Percutánea , Humanos , Clopidogrel , Inhibidores de Agregación Plaquetaria/efectos adversos , Citocromo P-450 CYP2C19/genética , Citocromo P-450 CYP2C19/metabolismo , Ticlopidina , Síndrome Coronario Agudo/genética , Hemorragia/etiología , Genotipo , Intervención Coronaria Percutánea/efectos adversos , Resultado del TratamientoRESUMEN
Glioblastoma (GBM) is one of the most aggressive primary malignant brain tumors. The major challenge is the lack of effective therapeutic drugs due to the blood-brain barrier (BBB) and tumor heterogeneity. Remdesivir (RDV), a new member of the nucleotide analog family, has previously been shown to have excellent antiviral effects and BBB penetration, and was predicted here to have anti-GBM effects. In vitro experiments, RDV significantly inhibited the growth of GBM cells, with IC50 values markedly lower than those of normal cell lines or the same cell lines treated with temozolomide. Moreover, in multiple mouse models, RDV not only distinctly inhibited the progression and improved the prognosis of GBM but also exhibited a promising biosafety profile, as manifested by the lack of significant body weight loss, liver or kidney dysfunction or organ structural damage after administration. Furthermore, we investigated the anti-GBM mechanism by RNA-seq and identified that RDV might induce apoptosis of GBM cells by enhancing endoplasmic reticulum (ER) stress and activating the PERK-mediated unfolded protein response. In conclusion, our results indicated that RDV might serve as a novel agent for GBM treatment by increasing ER stress and inducing apoptosis in GBM cells.
Asunto(s)
Neoplasias Encefálicas , Glioblastoma , Ratones , Animales , Neoplasias Encefálicas/patología , Glioblastoma/patología , Estrés del Retículo Endoplásmico , Temozolomida , Respuesta de Proteína Desplegada , Apoptosis , Línea Celular TumoralRESUMEN
Calcium/calmodulin-dependent kinase II delta (CaMKIIδ) is the predominant cardiac isoform and it is alternatively spliced to generate multiple variants. Variable variants allow for distinct localization and potentially different functions in the heart. Dysregulation of CaMKIIδ splicing has been demonstrated to be involved in the pathogenesis of heart diseases, such as cardiac hypertrophy, arrhythmia, and diastolic dysfunction. However, the mechanisms that regulate CaMKIIδ are incompletely understood. Here, we show that RNA binding motif protein 24 (RBM24) is a key splicing regulator of CaMKIIδ. RBM24 ablation leads to the aberrant shift of CaMKIIδ towards the δ-C isoform, which is known to activate the L-type Ca current. In line with this, we found marked alteration in Ca2+ handling followed by prolongation of the ventricular cardiac action potential and QT interval in RBM24 knockout mice, and these changes could be attenuated by treatment with an inhibitor of CaMKIIδ. Importantly, knockdown of RBM24 in human embryonic stem cell-derived cardiomyocytes showed similar electrophysiological abnormalities, suggesting the important role of RBM24 in the human heart. Thus, our data suggest that RBM24 is a critical regulator of CaMKIIδ to control the cardiac QT interval, highlighting the key role of splicing regulation in cardiac rhythm.
Asunto(s)
Cardiopatías , Empalme del ARN , Humanos , Animales , Ratones , Empalme del ARN/genética , Ventrículos Cardíacos , Miocitos Cardíacos , Potenciales de Acción/genética , Ratones Noqueados , Proteínas de Unión al ARN/genéticaRESUMEN
Recently, it was confirmed that ACE2 is the receptor of SARS-CoV-2, the pathogen causing the recent outbreak of severe pneumonia around the world. It is confused that ACE2 is widely expressed across a variety of organs and is expressed moderately but not highly in lung, which, however, is the major infected organ. Therefore, we hypothesized that there could be some other genes playing key roles in the entry of SARS-CoV-2 into human cells. Here we found that AGTR2 (angiotensin II receptor type 2), a G-protein coupled receptor, has interaction with ACE2 and is highly expressed in lung with a high tissue specificity. More importantly, simulation of 3D structure based protein-protein interaction reveals that AGTR2 shows a higher binding affinity with the Spike protein of SARS-CoV-2 than ACE2 (energy: -8.2 vs. -5.1 [kcal/mol]). A number of compounds, biologics and traditional Chinese medicine that could decrease the expression level of AGTR2 were predicted. Finally, we suggest that AGTR2 could be a putative novel gene for the entry of SARS-CoV-2 into human cells, which could provide different insight for the research of SARS-CoV-2 proteins with their receptors.
Asunto(s)
COVID-19/genética , COVID-19/virología , Receptor de Angiotensina Tipo 2/genética , Receptores Virales/genética , SARS-CoV-2 , Enzima Convertidora de Angiotensina 2/química , Enzima Convertidora de Angiotensina 2/fisiología , Antivirales/farmacología , COVID-19/fisiopatología , Biología Computacional , Simulación por Computador , Evaluación Preclínica de Medicamentos , Humanos , Modelos Moleculares , Mapas de Interacción de Proteínas , Receptor de Angiotensina Tipo 2/química , Receptor de Angiotensina Tipo 2/fisiología , Receptores Virales/química , Receptores Virales/fisiología , SARS-CoV-2/efectos de los fármacos , SARS-CoV-2/patogenicidad , SARS-CoV-2/fisiología , Serina Endopeptidasas/genética , Glicoproteína de la Espiga del Coronavirus/química , Glicoproteína de la Espiga del Coronavirus/fisiología , Transcriptoma/efectos de los fármacos , Internalización del VirusRESUMEN
In this paper, the problem of adaptive neural tracking control for a type of uncertain switched nonlinear nonlower-triangular system is considered. The innovations of this paper are summarized as follows: 1) input to state stability of unmodeled dynamics is removed, which is an indispensable assumption for the design of nonswitched unmodeled dynamic systems; 2) the design difficulties caused by the nonlower-triangular structure is handled by applying the universal approximation ability of radial basis function neural networks and the inherent properties of Gaussian functions, which avoids the restriction that the monotonously increasing bounding functions of the nonlower-triangular system functions must exist; and 3) multiple Lyapunov functions are utilized to develop a backstepping-like recursive design procedure such that the solvability of the adaptive neural tracking control issue of all subsystems is unnecessary. Based on the proposed controller design methods, it can be obtained that all signals in the closed-loop switched system remain bounded and the tracking error can eventually converge to a small neighborhood of the origin. In the simulation study, two examples are supplied to prove the practicability and feasibility of the developed design schemes.
RESUMEN
Clopidogrel therapy reduces the occurrence of major vascular events in acute coronary syndrome (ACS) patients, but treatment efficacy is variable. The present study aims to determine the mechanisms that underlie associations between certain miRNA polymorphisms and clinical outcomes of clopidogrel therapy. Our study focused on 9 miRNA single nucleotide polymorphisms in addition to CYP2C19*2 and CYP2C19*3. We found that the miR-605 rs2043556 AG genotype significantly decreased the risk of acute myocardial infarction (odds ratio, OR = 0.13, 95%CI 0.02-0.96, P = .045) and that the rs2043556 GG genotype significantly decreased the risk of unstable angina (OR = 0.19, 95%CI 0.05-0.65, P = .008) in ACS patients receiving clopidogrel therapy for more than one year. Dual-luciferase analysis indicated that miR-605 significantly decreased the mRNA expression of CYP2B6 and P2RY12 (P < .01). In cells treated with miR-605-A, the protein and mRNA expression of CYP2B6 and P2RY12 were significantly lower than that of cells treated with miR-605-G (P < .05). The results demonstrate that miR-605 targets the mRNA of the CYP2B6 and P2RY12 genes, and that rs2043556 A/G polymorphisms in miR-605 modulate the mRNA and protein expression of CYP2B6 and P2RY12 differently, which may impact the effect of clopidogrel in ACS patients.
Asunto(s)
Síndrome Coronario Agudo/tratamiento farmacológico , Síndrome Coronario Agudo/genética , Clopidogrel/uso terapéutico , Citocromo P-450 CYP2B6/metabolismo , MicroARNs/metabolismo , Antagonistas del Receptor Purinérgico P2Y/uso terapéutico , Receptores Purinérgicos P2Y12/metabolismo , Síndrome Coronario Agudo/metabolismo , Adulto , Anciano , Anciano de 80 o más Años , Clopidogrel/farmacología , Citocromo P-450 CYP2B6/genética , Femenino , Genotipo , Humanos , Masculino , MicroARNs/genética , Persona de Mediana Edad , Polimorfismo de Nucleótido Simple , Receptores Purinérgicos P2Y12/genéticaRESUMEN
Syncope is a clinical symptom for many kinds of diseases. The reasons for some syncope are still not clear even after a comprehensive and systematic examination, known as unexplained syncope. The clinical data of one patient with recurrent syncope, who had received the implanted loop recorder (ILR) in Xiangya Hospital, Central South University, were retrospectively analyzed. The instrument recorded the first syncope at a time of recurrence for the sustained ventricular tachycardia in 704 days after ILR. The patient was thus diagnosed as arrhythmic syncope and received an operation with implantable cardioverter defibrillator. The ILR is a new type of examination device for patients suffering from syncope with suspected cardiac rhythm due to its long monitoring time, low infection rate and high safety. It possesses high clinical value in the diagnosis of patients with arrhythmic syncope.